RBMS3 and ovarian carcinoma: Specifically, RBMS3 suppression was found to downregulate PD-L1 and enhance immune responses (Zhou et al., 2023), while metformin treatment increased RBMS3 expression and promoted ferroptosis in ovarian cancer cells (Zhao et al., 2025).